17 related articles for article (PubMed ID: 22358104)
1. Melanin-concentrating hormone receptor antagonism differentially attenuates nicotine experience-dependent locomotor behavior in female and male rats.
Kuebler IRK; Liu Y; Bueno Álvarez BS; Huber NM; Jolton JA; Dasari R; Wakabayashi KT
Pharmacol Biochem Behav; 2023 Nov; 232():173649. PubMed ID: 37793486
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders.
Di Ciano P; Hendershot CS; Le Foll B
Curr Top Behav Neurosci; 2022; 59():169-191. PubMed ID: 35704272
[TBL] [Abstract][Full Text] [Related]
3. Obesity and addiction: neurobiological overlaps.
Volkow ND; Wang GJ; Tomasi D; Baler RD
Obes Rev; 2013 Jan; 14(1):2-18. PubMed ID: 23016694
[TBL] [Abstract][Full Text] [Related]
4. Effects of the histamine H₃ receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice.
Kruk M; Miszkiel J; McCreary AC; Przegaliński E; Filip M; Biała G
Pharmacol Rep; 2012; 64(6):1316-25. PubMed ID: 23406742
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
Fox GB; Esbenshade TA; Pan JB; Radek RJ; Krueger KM; Yao BB; Browman KE; Buckley MJ; Ballard ME; Komater VA; Miner H; Zhang M; Faghih R; Rueter LE; Bitner RS; Drescher KU; Wetter J; Marsh K; Lemaire M; Porsolt RD; Bennani YL; Sullivan JP; Cowart MD; Decker MW; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):176-90. PubMed ID: 15608077
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
[TBL] [Abstract][Full Text] [Related]
7. Adenosine (A)(2A)receptor modulation of nicotine-induced locomotor sensitization. A pharmacological and transgenic approach.
Jastrzębska J; Nowak E; Smaga I; Bystrowska B; Frankowska M; Bader M; Filip M; Fuxe K
Neuropharmacology; 2014 Jun; 81():318-26. PubMed ID: 24632528
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the abuse liability of ABT-288, a novel histamine H₃ receptor antagonist.
Hudzik TJ; Basso A; Boyce-Rustay JM; Bracken W; Browman KE; Drescher K; Esbenshade TA; Loberg LI; Lynch JJ; Brioni JD
Psychopharmacology (Berl); 2013 Jul; 228(2):187-97. PubMed ID: 23455597
[TBL] [Abstract][Full Text] [Related]
9. Effects of the histamine H3 receptor antagonist ABT-239 on acute and repeated nicotine locomotor responses in rats.
Miszkiel J; Kruk M; McCreary AC; Przegaliński E; Biała G; Filip M
Pharmacol Rep; 2011; 63(6):1553-9. PubMed ID: 22358104
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
